Skip to main content

Market Overview

Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy

Share:

Acceleron Pharma Inc (NASDAQ: XLRN) has two ongoing Phase III trials of luspatercept in lower-risk MDS and beta thalassemia, both of which have a 60 percent probability of success, BTIG’s Ling Wang said in a report. He reinitiated coverage of the company with a Buy rating and a price target of $46.

Analyst Wang believes that upside to Acceleron’s shares would be driven in the near term by updates on response duration from the two Phase II luspatercept trials as well as initial data from MDS expansion trials. Acceleron has partnered with Celgene Corporation (NASDAQ: CELG) [Rated: Buy, PT: $138] for luspatercept.

Luspatercept In MDS

Luspatercept has exhibited impressive efficacy in MDS, with durable effect in improving hemoglobin and reducing transfusion burden by 50 percent in a population without effective therapy.

Luspatercept In Beta Thalassemia

“As ~67% and 83% of the transfusion-dependent patients in the Phase II base and extension studies achieved over 33% reduction in RBC transfusion, the primary endpoint in the Phase III BELIEVE trial, we see a good chance of Phase III success,” Wang wrote.

Acceleron has a broad pipeline, including sotatercept [Phase II], dalantercept [Phase II RCC data expected in 4Q16] andAC-083 [Phase II planned for muscle-related indications].

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for XLRN

DateFirmActionFromTo
Oct 2021JefferiesInitiates Coverage OnHold
Oct 2021Raymond JamesDowngradesStrong BuyMarket Perform
Oct 2021Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for XLRN

View the Latest Analyst Ratings

 

Related Articles (XLRN)

View Comments and Join the Discussion!

Posted-In: btig Ling WangAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com